Bristol Myers Squibb (BMS) has shared positive overall survival (OS) results from a late-stage study of its Opdivo (nivolumab) combination in non-small cell lung cancer (NSCLC).

Cantargia AB (STU:7V3) reports reduced operating expenses, a successful rights issue, and strategic focus on immune-inflammatory assets amid management transition.

A new study shows that neutralising GDF-15 restores immune response in advanced cancers resistant to PD-1 blockade.

"Woman," "elderly," and "disabled" were among a list of banned words reportedly circulating within the FDA, which the White ...

Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the “Company”), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte ...

We recently compiled a list of the 10 Best Non-Tech Stocks to Buy Now for Long Term. In this article, we are going to take a ...

The following is a summary of "Prophylactic cranial irradiation improved the prognosis in pT1-2N0M0 small cell lung cancers ...

A spaghetti dinner fundraiser is slated on March 1 in Free Soil to support firefighter Robin Arlt, battling stage 4 lung cancer.